The metabolism of nucleotides in plants is a fundamental process underpinning growth, development and adaptive responses to environmental cues. Central to these processes are the de novo synthesis and ...

Novo Nordisk has won the race to secure approval from the U.S. Food and Drug Administration for the first weight-loss drug to be administered orally. Jules Rimmer is a markets reporter in ...

Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it picked up a year ago, was hit with a warning letter from the FDA last month. The ...

Novo Nordisk first to market with Wegovy pill Analysts see potential but question if pills are a 'game changer' Advantage for Novo could be short-lived, analysts say The approval of Novo's Wegovy pill ...

Novo Nordisk NOVO.B1.08%increase; green up pointing triangle filed for U.S. Food and Drug Administration approval of CagriSema, a once-weekly shot that combines two compounds to treat obesity.

When Novo Nordisk launched Wegovy, its pioneering weight-loss jab, in America in June 2021, it felt like it was “running into a dark tunnel”, recalls Maziar Mike Doustdar, who took over as the Danish ...

FDA approves Novo Nordisk's weight-loss pill Novo aims to regain market share from Eli Lilly Pill broadens potential patient pool The pill is 25 milligrams of semaglutide, the same active ingredient ...

The pole position in the GLP-1 weight loss space is currently held by Eli Lilly. Novo Nordisk was the early leader, showing that being first doesn't always mean you stay at the head of the pack.

After ushering in a new era of obesity treatment with its GLP-1 medicine Wegovy earlier in the decade, Novo Nordisk is making history again with the first FDA approval of a GLP-1 pill for weight loss.

The U.S. Food and Drug Administration on Dec. 22 approved a pill version of Novo Nordisk’s weight-loss drug Wegovy, the first daily oral medication for obesity treatment. The once-daily tablet — ...

These two healthcare stocks are top names to invest in, but they haven't both been doing well of late. Eli Lilly has generated $25 billion in revenue from its fast-growing GLP-1 drugs this year. Novo ...